What is SIGA Technologies?
Founded in 1995 and headquartered in New York, SIGA Technologies, Inc. operates at the intersection of biotechnology and national security. The company is primarily recognized for the development and commercialization of TPOXX, a proprietary orally administered antiviral medication designed to treat orthopoxvirus infections. By focusing on high-stakes medical solutions, SIGA has carved out a unique market niche, providing essential countermeasures that address both public health emergencies and specialized defense requirements. Their operational model emphasizes rigorous research and development, ensuring that their medical solutions meet the stringent demands of government and commercial health agencies alike.
How much funding has SIGA Technologies raised?
SIGA Technologies has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (1997): $12.5M, investors not publicly disclosed
Key Investors in SIGA Technologies
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SIGA Technologies?
With this major enterprise-level funding, SIGA Technologies is well-positioned to scale its commercialization efforts and expand its research capabilities. The strategic allocation of this capital will likely focus on enhancing the distribution of its lead antiviral assets and exploring new therapeutic applications for its existing platform. As the global landscape for biosecurity continues to evolve, SIGA remains a pivotal entity, poised to capitalize on increased demand for robust, rapid-response medical countermeasures. Investors and stakeholders will be monitoring the company's ability to translate this financial backing into sustained growth and expanded market penetration within the competitive biopharmaceutical sector.
See full SIGA Technologies company page
